Clinical trial
Effect of a Reduced Dose on Cognitive Side Effects of Enzalutamide in Frail (Metastatic) Castration-resistant Prostate Cancer Patients (REDOSE)
NCT03927391 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of a Reduced Dose on Cognitive Side Effects of Enzalutamide in Frail (Metastatic) Castration-resistant Prostate Cancer Patients (REDOSE)
- Lead sponsor
- Radboud University Medical Center
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- May 30, 2019
- Completion date
- January 8, 2024
- Enrollment
- 57 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.